

4DMedical strengthens executive group: experienced MedTech CFO appointed

24 June 2022

Highlights

- 4DMedical has appointed experienced ASX-listed MedTech CFO Simon Glover as the Company's new CFO
- Mr Glover has significant corporate experience in relation to commercialisation, business strategy, cashflow management and a track record of driving revenue growth
- Mr Glover has served in senior finance leadership roles for MedAdvisor Limited (ASX: MDR), Coles Group (ASX:COL), Tabcorp Holdings Limited (ASX:TAH), Jetstar (ASX:QAN) and KPMG
- 4DMedical's exiting CFO Heath Lee will remain at 4DMedical until 29 July to ensure the smooth transition of his responsibilities to Mr Glover

Melbourne, Australia, 24 June 2022: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") is pleased to announce it has appointed experienced ASX-listed MedTech CFO Simon Glover as the Company's new CFO effective 25th July 2022.

Mr Glover has significant corporate experience in relation to commercialisation, business strategy, cashflow management and a track record of driving revenue growth. He joins 4DMedical after three years serving MedAdvisor Limited (ASX: MDR) in the role of CFO.

Mr Glover is in a unique position to leverage his experience at MedAdvisor, a SaaS MedTech with global operations across the US, UK, Asia, and Australia. Mr Glover has also held senior finance leadership roles for Coles Group (ASX:COL), Tabcorp Holdings Limited (ASX:TAH), Jetstar (ASX:QAN) and KPMG.

4DMedical's exiting CFO, Heath Lee, will remain at 4DMedical until 29 July to ensure the smooth transition of his responsibilities to Mr Glover.

Commenting on the CFO transition, 4DMedical Managing Director & CEO Andreas Fouras said:

"After a comprehensive executive search which attracted several exceptional candidates, 4DMedical is excited to have Simon join our executive group as CFO. As 4DMedical continues its commercialisation journey, a fresh perspective, bolstered by significant and relevant industry experience, is welcomed. We look forward to Simon making a meaningful contribution as we accelerate commercialisation of our technology."

On behalf of the Board, I would like to thank Heath for his commitment to 4DMedical over the past six years, initially as a Board member and more recently as CFO, where he played a significant role in the IPO. Heath is well regarded having created a high performing finance and administration team, and we wish him all the best with his future endeavours."



Commenting on his new role, incoming 4DMedical CFO Simon Glover said:

"I am very much looking forward to commencing in the role of CFO for 4DMedical and supporting the Company to commercialise its revolutionary technology. I have operated at the most senior level in professional services across multiple industries, including SaaS MedTech, and approach my roles with a highly commercial results-driven focus. I believe 4DMedical has an extremely exciting future and I will be working hard to contribute through a high level of strategic insight, leadership and integrity."

-ENDS-

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Melanie Leydin
Company Secretary
companysecretary@4dmedical.com

Media

Julia Maguire
+ 61 419 815 386
julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand lung function of patients with respiratory diseases.

Through its flagship patented XV Technology™, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS™), which is the first and only modality that can dynamically quantify ventilation throughout the lungs. It additionally exposes the patient to lower levels of radiation relative to other diagnostic methods, a clear advantage when disease progression and therapeutic effectiveness need to be regularly monitored.

XV LVAS™ reports are prepared utilising 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the company's own revolutionary XV Scanner.

To learn more, please visit: www.4dmedical.com